WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of new preclinical data with the Company’s experimental therapies IMGN529 and IMGN779 to be made at the upcoming American Society of Hematology (ASH) annual meeting to be held December 5-8, 2015 in Orlando, FL.
